Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Affimed Ord Shs
(NQ:
AFMD
)
4.200
-0.010 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Affimed Ord Shs
< Previous
1
2
3
4
5
6
Next >
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
August 03, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
July 31, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
June 22, 2023
From
Affimed N.V.
Via
GlobeNewswire
Analyst Ratings for Affimed
May 24, 2023
Via
Benzinga
Affimed: Q1 Earnings Insights
May 23, 2023
Via
Benzinga
Affimed's Earnings Outlook
May 22, 2023
Via
Benzinga
Earnings Preview For Affimed
March 22, 2023
Via
Benzinga
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
June 09, 2023
From
Affimed N.V.
Via
GlobeNewswire
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
June 05, 2023
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!'
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 05, 2023
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
June 03, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
May 25, 2023
From
Affimed N.V.
Via
GlobeNewswire
Earnings Scheduled For May 23, 2023
May 23, 2023
Companies Reporting Before The Bell • ATRenew (NYSE:RERE) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million.
Via
Benzinga
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
May 23, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
May 23, 2023
From
Affimed N.V.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 22, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Via
InvestorPlace
Affimed Announces Annual General Meeting of Shareholders
May 22, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
May 16, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
May 11, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
April 26, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
April 17, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
April 16, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
April 06, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
March 29, 2023
From
Affimed N.V.
Via
GlobeNewswire
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
Affimed Reports 2022 Financial Results and Operational Progress
March 23, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
March 16, 2023
From
Affimed N.V.
Via
GlobeNewswire
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
March 14, 2023
From
Affimed N.V.
Via
GlobeNewswire
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
March 09, 2023
From
Affimed N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.